American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 358-361 , September 2007

Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A View From Europe

  • Iain C. Macdougall, MD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Iain C. Macdougall, MD, Renal Unit, King’s College Hospital, London SE5 9RS United Kingdom.

  • Image Result

    Unadjusted weekly epoetin (Epo) dose and mean hemoglobin level in prevalent hemodialysis patient by country as seen in 12 countries contributing data to the Dialysis Outcomes and Practice Patterns Stu

    Unadjusted weekly epoetin (Epo) dose and mean hemoglobin level in prevalent hemodialysis patient by country as seen in 12 countries contributing data to the Dialysis Outcomes and Practice Patterns Study (DOPPS) II in 2002-2003. **US, data for patients excluding those administered >36,000 units per week of epoetin to account for skewed data. Abbreviations: ANZ, Australia/New Zealand; BE, Belgium; CA, Canada; FR, France; GE, Germany; IT, Italy; JA, Japan; SP, Spain; SW, Sweden; UK, United Kingdom. Reprinted with permission from Pisoni et al.2

  • Image Result
    Mean epoetin dose by hemodialysis treatment center in the United Kingdom (data extracted from the UK Renal Registry, Eighth Annual Report, December 2005, p. 144).7

    Mean epoetin dose by hemodialysis treatment center in the United Kingdom (data extracted from the UK Renal Registry, Eighth Annual Report, December 2005, p. 144).7

PII: S0272-6386(07)01039-6

doi: 10.1053/j.ajkd.2007.07.010

American Journal of Kidney Diseases
Volume 50, Issue 3 , Pages 358-361 , September 2007